.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Longer follow-up is useful when comparing deep brain stimulation targets because early improvements may evolve over time. In this multicentre randomized controlled trial, patients with Parkinson disease were assigned to globus pallidus internus or subthalamic nucleus stimulation and followed for 36 months. Motor function improved significantly with both approaches, and the degree of improvement was similar between targets. Quality of life improved early but the magnitude of improvement diminished over time. Neurocognitive outcomes provided an additional distinction: the Mattis Dementia Rating Scale declined faster in the STN group, while other cognitive measures showed more gradual change in both groups. The findings reinforce that DBS target selection should not be reduced to a single motor score. For HCPs, a complete preoperative assessment of cognition, mood, medication burden, dyskinesia, gait and patient priorities can help identify the most appropriate target. The trial also highlights the importance of long-term follow-up because the benefit-risk profile of different targets is not captured by the first postoperative year alone. This evidence is directly relevant to IANCON's movement-disorder and DBS discussions.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Longer follow-up is useful when comparing deep brain stimulation targets because early improvements may evolve over time. In this multicentre randomized controlled trial, patients with Parkinson disease were assigned to globus pallidus internus or subthalamic nucleus stimulation and followed for 36 months. Motor function improved significantly with both approaches, and the degree of improvement was similar between targets. Quality of life improved early but the magnitude of improvement diminished over time. Neurocognitive outcomes provided an additional distinction: the Mattis Dementia Rating Scale declined faster in the STN group, while other cognitive measures showed more gradual change in both groups. The findings reinforce that DBS target selection should not be reduced to a single motor score. For HCPs, a complete preoperative assessment of cognition, mood, medication burden, dyskinesia, gait and patient priorities can help identify the most appropriate target. The trial also highlights the importance of long-term follow-up because the benefit-risk profile of different targets is not captured by the first postoperative year alone. This evidence is directly relevant to IANCON's movement-disorder and DBS discussions.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
